Texas Liver Institute

Running trials

• Recruiting

  Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions

  NCT07654283· Phase 2· AusperBio Therapeutics Inc.· Source

• Recruiting

  A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment

  NCT07559474· Phase 1· Incyte Corporation· Source

• Recruiting

  A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

  NCT07253285· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis

  NCT05979779· Phase 2· Rivus Pharmaceuticals, Inc.· Source

• Recruiting

  Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics

  NCT05490888· Phase 1· PharmaIN· Source

• Active, not recruiting

  A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

  NCT04849728· Phase 3· Inventiva Pharma· Source

• Active, not recruiting

  A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

  NCT04951219· Phase 3· Madrigal Pharmaceuticals, Inc.· Source

• Active, not recruiting

  A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

  NCT03900429· Phase 3· Madrigal Pharmaceuticals, Inc.· Source

• Active, not recruiting

  Clinical Trial Multi-analyte Blood Test

  NCT03694600· Helio Genomics· Source

• Active, not recruiting

  Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)

  NCT03301506· Phase 3· Gilead Sciences· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Hepatitis B1 recruiting
• Liver cirrhosis1 recruiting
• Obesity1 recruiting

Closed trials

• Completed

  A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis.

  NCT06525311· Phase 1· Kowa Research Institute, Inc.· Source

• Completed

  Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment

  NCT06535399· Phase 1· Celgene· Source

• Completed

  A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment

  NCT06352528· Phase 1· Bristol-Myers Squibb· Source

• Completed

  A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH

  NCT05591079· Phase 2· Cascade Pharmaceuticals, Inc· Source

• Terminated

  A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4

  NCT07052682· Phase 1· Takeda· Source

• Completed

  Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434

  NCT05484206· Phase 1· Vir Biotechnology, Inc.· Source

• Completed

  A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.

  NCT05329623· Phase 1· Novartis Pharmaceuticals· Source

• Completed

  Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis

  NCT05104853· Phase 1/2· COUR Pharmaceutical Development Company, Inc.· Source

• Completed

  A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

  NCT04771273· Phase 2· Boehringer Ingelheim· Source

• Terminated

  Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

  NCT04365868· Phase 2/3· Galectin Therapeutics Inc.· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Primary biliary cholangitis10 works · 3 trials